Investors were unimpressed by the company's trial results for an ulcerative colitis therapy.
The company has several promising autoimmune therapies.
The biotech benefits from a much larger peer's recent FDA approval.
Excellent safety, tolerability and pharmacokinetic profile Robust dose-dependent target engagement as measured by ex vivo IL-1β release assay Phase 2...
ENCINITAS, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company...
Topline Phase 1 data for our allosteric TYK2 inhibitor, VTX958, expected in early Q3 2022 Topline Phase 1 data for our selective NLRP3 inhibitor, VTX2735,...
ENCINITAS, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company...
Topline Phase 1 data for our allosteric TYK2 inhibitor, VTX958, expected in early Q3 2022 Topline Phase 1 data for our oral, selective NLRP3 inhibitor,...
ENCINITAS, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx” or the “Company”), a clinical-stage...
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical...